Skip to main content
Premium Trial:

Request an Annual Quote

Celera Sells Animal Genomics Unit to MetaMorphix

NEW YORK, March  4 - Celera Genomics, in a move to hasten its metamorphosis as a drug developer, has sold its AgGen animal genomics and genotyping business to MetaMorphix, the companies said on Monday.

 

MetaMorphix will use the livestock databases to develop new products, according to a statement. The company also gets a subscription to Celera's Discovery System bioinformatics and annotation platform.

 

In return, Celera has acquired a minority interest in the company and will receive future royalties on new products that MetaMorphix develops by using the database.

 

The companies did not disclose financial details of the agreement.

 

MetaMorphix, based in Savage, Md., uses genomics and proteomics to improve livestock and other animals. It focuses on developing products that can accelerate animal growth and speed, and improve meat production, reduce waste, and decrease the use of antibiotics and hormones. The company is also working on products related to population control and behavior in pets.

 

In December, Celera sold the plant side of its AgGen division to Paradigm in a $2 million stock deal.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.